Sr. Research Fellow
Boehringer Ingelheim Pharmaceuticals, Inc.
Danbury, Connecticut
Dr. Chen obtained his Ph.D. degree in organic chemistry from the University of Mons, Belgium. After postdoctoral training at the Pacific Northwest National Laboratory in Washington, he joined 3M Pharmaceuticals where he became a group leader responsible for metabolism and PK studies. He then joined Boehringer Ingelheim Pharmaceuticals to lead a group primarily responsible for metabolism and bioanalysis in support of drug development. In recent years, his group has been providing bioanalytical support to the development of therapeutic proteins and oligonucleotides as well as viral vector-based gene therapy. His group has developed a number of LC/MS assays for various biotherapeutic proteins such as nanobodies, Fabs, bispecifics and mAbs, siRNA and viral proteins. He was the pioneer of developing and applying immunocapture-LC/MS methodology for simultaneous anti-drug antibody isotyping and semi-quantitation. His recent research focuses on assessment of in vivo critical quality attributes of biologic therapeutics, target engagement, biomarker and mechanistic investigation of biotherapeutics and ATMPs. Dr. Chen has more than 40 publications in peer-reviewed journals, and has served as editorial board member of several scientific journals and IQ consortium workgroups. Dr. Chen has given numerous talks at international conferences and taught various training courses sponsored by pharmaceutical industry.
Disclosure information not submitted.
Keynote: Development of Oligonucleotide Therapeutics
Wednesday, May 15, 2024
1:00 PM – 2:00 PM PT